By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



116 Village Boulevard
Suite 200
Princeton  New Jersey  08540  U.S.A.
Phone: 609-951-2206 Fax: 609-213-5287



Company News
ViroStatics AV-HALT Phase 2a Study in HIV/AIDS Paper Published in PLoS ONE 10/22/2012 9:19:40 AM
ViroStatics CEO, Dr. Franco Lori, to Speak at the International Track During Pennsylvania Biotech 2011 10/24/2011 10:30:39 AM
ViroStatics CEO, Franco Lori, MD, Presents Late Breaker on Novel AV-HALT HIV Therapy at the 2011 International AIDS Society Pathogenesis Conference 7/20/2011 8:42:02 AM
ViroStatics CEO Franco Lori, MD to Present Novel Immune-based Technologies for HIV/AIDS and Chronic Diseases at the 2011 Biotechnology Industry Organization (BIO) International Conference 6/27/2011 10:02:38 AM
ViroStatics Demonstrates Clinical Proof of Concept for Dual Antiviral Anti-Hyperactivation AV-HALT Drugs 3/2/2011 8:55:15 AM
Immunacia’s ViroStatics Reports Phase II Data on VS411, an AV-HALT for Treating HIV/AIDS, During the XVIII International AIDS Conference 7/19/2010 9:43:17 AM
ViroStatics and Vichem Chemie Announce Strategic Partnership to Identify and Develop Kinase Inhibitors for the Treatment of HIV/AIDS and Other Chronic Diseases 6/11/2010 10:49:15 AM
Dr. James Chafouleas Joins ViroStatics and Genetic Immunity as Strategic Adviser 5/3/2010 3:17:56 PM
ViroStatics' Dr. Franco Lori to Present During 2009 Biotechnology Industry Organization (BIO) International Convention in Atlanta 5/18/2009 11:02:50 AM
ViroStatics Acquires Library of Anti-Cancer/Antiviral Compounds From the University of Siena 4/14/2009 11:58:46 AM